Form 4: NewAmsterdam Pharma COO Executes Pre-Planned Stock Option Exercises and Sales

NewAmsterdam Pharma Co N.V.'s Chief Operating Officer, Douglas F. Kling, engaged in significant stock transactions, exercising options and selling shares under a Rule 10b5-1 trading plan.

Summary

• Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V. (NAMS), exercised options to acquire a total of 100,000 Ordinary Shares on June 16, 2025.
• Specifically, Mr. Kling acquired 78,101 Ordinary Shares by exercising options at a price of $10.00 per share.
• Additionally, he acquired 21,899 Ordinary Shares by exercising options at a price of $10.90 per share.
• Following these exercises, Mr. Kling sold a total of 100,000 Ordinary Shares on the same date, June 16, 2025.
• The sales included 81,891 shares at a weighted average price of $19.19 per share, with individual transactions ranging from $18.60 to $19.59.
• Another 18,109 shares were sold at a weighted average price of $19.75 per share, with individual transactions ranging from $19.60 to $20.21.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Kling in advance.
• After these transactions, Mr. Kling directly beneficially owned 44,000 Ordinary Shares.
• He also beneficially owned 372,829 options with an exercise price of $10.00 and 261,314 options with an exercise price of $10.90.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, which is a neutral event. The fact that the options were significantly in-the-money and sold at a profit reflects positively on the company's stock performance and the executive's compensation.

Positives

• The Chief Operating Officer realized a substantial profit by exercising options at significantly lower prices ($10.00 and $10.90) and selling the shares at higher market prices (weighted averages of $19.19 and $19.75), indicating the company's stock appreciation.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which demonstrates transparency and mitigates concerns about insider trading based on non-public information.

Negatives

• The sale of a significant number of shares by a key executive, even under a pre-planned arrangement, could be perceived by some investors as a reduction in insider ownership and potentially a signal of limited future upside, though it is a common practice for executives to diversify or manage tax liabilities.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, specifically the exercise of stock options and subsequent sale of shares. It does not provide broader industry context or strategic updates for NewAmsterdam Pharma Co N.V. beyond the executive's personal equity management.

Stakeholder Impact

• Shareholders: May note the sale of shares by a key executive, but the pre-planned nature under Rule 10b5-1 mitigates concerns about opportunistic selling. The profit realized by the COO reflects positively on the stock's performance.
• Employees: No direct impact mentioned, but executive compensation and equity management practices are generally transparent.

Next Steps

• Continued vesting of the remaining 372,829 options granted on November 22, 2022, in equal monthly installments until November 22, 2026.
• Continued vesting of the remaining 261,314 options granted on January 1, 2023, in equal monthly installments for three years after the initial 25% vesting.

Key Dates

Keywords

NewAmsterdam Pharma, NAMS, SEC Form 4, Insider Trading, Stock Options, Share Sale, Chief Operating Officer, Douglas F. Kling, Rule 10b5-1 Plan, Equity Compensation